The impact of rarity in NICE’s health technology appraisals

Comparing access to orphan medicinal products in Europe

(2019) Bernarda Zamora et al.   Orphanet Journal of Rare Diseases

Therapies for rare diseases: therapeutic modalities, progress and challenges ahead

(2019) Erik Tambuyzer et al.   NATURE REVIEWS DRUG DISCOVERY

From scientific discovery to treatments for rare diseases – the view from the National Center for Advancing Translational Sciences – Office of Rare Diseases Research

(2018) Petra Kaufmann et al.   Orphanet Journal of Rare Diseases

HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries

(2017) Elena Nicod et al.   HEALTH POLICY

Addressing challenges in the diagnosis and treatment of rare genetic diseases

(2017) Kym M. Boycott et al.   NATURE REVIEWS DRUG DISCOVERY

SOCIETAL VIEWS ON NICE, CANCER DRUGS FUND AND VALUE-BASED PRICING CRITERIA FOR PRIORITISING MEDICINES: A CROSS-SECTIONAL SURVEY OF 4118 ADULTS IN GREAT BRITAIN

(2012) Warren G. Linley et al.   HEALTH ECONOMICS

Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 2007

(2010) Javier Orofino et al.   Applied Health Economics and Health Policy